Novartis drug Afinitor® recommended by CHMP for EU approval to treat select GI
Novartis announced the CHMP of the European Medicines Agency adopted a positive opinion for Afinitor® (everolimus) tablets for treatment of unresectable or metastatic, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal or lung origin in adults with progressive disease. April 29, 2016